{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T21:49:53Z","timestamp":1769723393140,"version":"3.49.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:p>Residual carcinoma confined to lymphovascular spaces following neoadjuvant chemotherapy (NAC) for invasive breast carcinoma is an uncommon finding. We studied pathologic features and outcome for patients with pure intralymphatic carcinoma (PIC) following NAC, a pattern of residual disease reported to have a poor outcome in the only previously published series of this entity. Six of 284 (2.1%) patients treated with NAC were studied. All 6 patients had axillary lymph node involvement before NAC. Tumors were triple-negative (n=3) and HER2+ (n=3: 2 ER+, 1 ER\u2212). Two patients presented with clinical findings of inflammatory carcinoma. Three of 5 pre-NAC core biopsies showed lymphovascular invasion. Three patients showed complete clinical response to NAC, and 3 showed partial response. Post-NAC surgical specimens showed foci of intralymphatic carcinoma in the breast spanning an extent of 0.5 mm to 0.5 cm. Residual ductal carcinoma in situ was present in 2 cases. Four of 6 patients converted to node-negative following NAC. One patient had distant metastasis at presentation and 1 patient died of pulmonary embolism 2 months after surgery. Three of the 4 remaining patients developed distant metastasis, of which 2 first recurred locally (in mean follow-up of 46.5 mo). Patients with PIC had significant greater risk for relapse (hazard ratio, 10.18 [1.97, 52.58]; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.006) compared with other NAC-treated patients, after controlling for residual lymph node involvement, tumor size, tumor subtype, histologic grade, and age. Residual PIC following NAC is associated with poor outcome, including in patients that are node-negative following NAC.<\/jats:p>","DOI":"10.1097\/pas.0000000000000896","type":"journal-article","created":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T15:05:11Z","timestamp":1498575911000},"page":"1275-1282","source":"Crossref","is-referenced-by-count":17,"title":["Residual Pure Intralymphatic Breast Carcinoma Following Neoadjuvant Chemotherapy Is Indicative of Poor Clinical Outcome, Even in Node-Negative Patients"],"prefix":"10.1097","volume":"41","author":[{"given":"Esther","family":"Cheng","sequence":"first","affiliation":[{"name":"Pathology and Laboratory Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Ko","sequence":"additional","affiliation":[{"name":"Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy-Ann","family":"Moo","sequence":"additional","affiliation":[{"name":"Surgery, Weill Cornell Medicine, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Andreopoulou","sequence":"additional","affiliation":[{"name":"Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed A.","family":"Hoda","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy M.","family":"D\u2019Alfonso","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27","volume":"26","author":"Rastogi","year":"2008","journal-title":"J Clin Oncol"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/PAS.0b013e31817fbdb4","article-title":"Pure and predominantly pure intralymphatic breast carcinoma after neoadjuvant chemotherapy: an unusual and adverse pattern of residual disease","volume":"33","author":"Rabban","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/modpathol.2015.74","article-title":"Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group","volume":"28","author":"Provenzano","year":"2015","journal-title":"Mod Pathol"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1200\/JCO.2002.20.5.1304","article-title":"Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes","volume":"20","author":"Rouzier","year":"2002","journal-title":"J Clin Oncol"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"9304","DOI":"10.1200\/JCO.2005.02.5023","article-title":"Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy","volume":"23","author":"Hennessy","year":"2005","journal-title":"J Clin Oncol"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10549-016-3837-5","article-title":"Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy","volume":"157","author":"Liu","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1517\/17425240903085128","article-title":"Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies","volume":"6","author":"Xie","year":"2009","journal-title":"Expert Opin Drug Deliv"},{"key":"R11-20230922","first-page":"893","article-title":"Effects of preoperative chemotherapy on the morphology of resectable breast carcinoma","volume":"9","author":"Sharkey","year":"1996","journal-title":"Mod Pathol"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s12282-010-0211-z","article-title":"Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer?","volume":"18","author":"Uematsu","year":"2011","journal-title":"Breast Cancer"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/sj.bjc.6603152","article-title":"Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study","volume":"94","author":"Van den Eynden","year":"2006","journal-title":"Br J Cancer"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/modpathol.3800457","article-title":"Comparison of the diagnostic accuracy of lymphatic endothelium markers: Bayesian approach","volume":"18","author":"Evangelou","year":"2005","journal-title":"Mod Pathol"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1136\/jcp.43.9.752","article-title":"JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections","volume":"43","author":"Parums","year":"1990","journal-title":"J Clin Pathol"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000478-201709000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:24:39Z","timestamp":1695421479000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000478-201709000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000000896","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}